Drug Profile
Aldafermin - NGM Biopharmaceuticals
Alternative Names: M 52; NGM 282Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator NGM Biopharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Laxatives; Recombinant proteins
- Mechanism of Action FGF19 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Non-alcoholic steatohepatitis
Highest Development Phases
- Phase II Diarrhoea; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
- No development reported Constipation; Type 2 diabetes mellitus
Most Recent Events
- 11 Mar 2024 NGM Biopharmaceuticals plans a registrational phase II trial for Primary Sclerosing Cholangitis in 2024
- 09 Jan 2024 Aldafermin is still in phase II trials for Primary sclerosing cholangitis (Monotherapy, Combination therapy) in the US, United Kingdom, Netherlands, France
- 10 Nov 2023 Efficacy and adverse event data from a phase IIb ALPINE 4 trial in Non alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)